ATP13A2 and Parkinson disease: Moreover, the other, more rare mutations, including PARK9 (ATP13A2; MIM #610513), PARK14 (PLA2G6; MIM #612953), PARK15 (FBXO7; MIM #260300), PARK19 (DNAJC6; MIM #615528), PARK20 (SYNJ1; MIM #615530), PARK23 (VPS13C; MIM #616840), and PODXL (MIM #602632) have been implicated in parkinsonism characterized by juvenile onset and atypical clinical signs (5, 7–10).